Azitra, Inc. (AZTR) Stock

Azitra, Inc. (AZTR) is a Healthcare stock trading at $0.13 (as of 2026-08-21), with a market capitalization of $7.99M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Understand Azitra, Inc.: how it makes money

Azitra, Inc. is a pre-clinical biopharmaceutical company developing precision dermatology therapies using engineered proteins and live biotherapeutic products, including ATR-12, ATR-04, and ATR-01; the provided facts do not describe its revenue source or how it makes money today.

Azitra's profit model (as a developing biopharmaceutical) depends on successfully advancing and validating its dermatology pipeline programs (ATR-12, ATR-04, ATR-01), since the provided information shows no meaningful revenue for the latest period.

Business quality (Weak): Limited, pipeline-focused company facts are provided, and there are no official reportable segment revenue breakdowns or operational KPI labels available in the inputs.

Bull case

Pipeline breadth across skin diseases: Azitra is developing multiple therapies for precision dermatology, including ATR-12 for Netherton syndrome, ATR-04 for the papulopustular rash experienced by cancer patients on EGFR inhibitors, and ATR-01 for ichthyosis vulgaris.
Dual platform approach: The company uses engineered proteins (ATR-01) and live biotherapeutic products, via genetically modified strains of S. epidermidis (ATR-12 and ATR-04), to treat skin diseases.

Bear case

No disclosed operating KPIs or segments: The provided inputs do not include operational KPI labels or reportable segment structure, which makes it harder to track day-to-day business drivers from the given information.
Development-stage uncertainty plus losses: The inputs describe Azitra as pre-clinical, and the latest reported period shows revenue of 0.0B with a very negative operating margin, indicating ongoing operating losses.

Valuation — source: SEC EDGAR (first-party)
Price	$0.13
Market Cap	$7.99M
Price / Book	1.09
Price / Sales	1065.82
FCF Yield	-239.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-167.3%
Current Ratio	4.86
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-5.1%
FCF Growth (YoY)	10.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-24.78 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	GEODE CAPITAL MANAGEMENT, LLC ($109951.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Francisco D. Salva
Employees	12
Country	US
IPO Date	2023-06-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.